Home / News / BioBlast™ Archive

BIOSIMILARS UPDATES

Our BioBlast™ Archive

Explore biosimilar news updates and biologics updates (BioBlast®) at Pearce IP.

Pearce IP BioBlast®: w/e 08 October 2021

27 Sep 21 | CA | Apobiologix announced that Health Canada has approved Bambevi® (biosimilar bevacizumab) in combination with chemotherapy to treat specific types of colorectal, lung, brain and ovarian cancer. 02 Oct 21 | A new study published in...

Pearce IP BioBlast®: w/e 01 October 2021

27 Sep 21 | Hikma Pharmaceuticals announced that it will acquire Custopharm for an initial cash consideration of USD $375 million with a further USD $50 million in contingent consideration payable upon the achievement of certain commercial...

Pearce IP BioBlast®: w/e 24 September 2021

18 Sep 21 | Merck announced that the first results from Ph III trials of Keytruda® (pembrolizumab) showed a statistically significant and clinically meaningful improvement in recurrence-free survival compared to placebo in patients with resected...

Pearce IP BioBlast®: w/e 17 September 2021

13 Sep 21 | Samsung Bioepis reported on a five-year follow-up study comparing ONTRUZANT® (trastuzumab biosimilar) with reference trastuzumab in early or locally advanced HER2 positive breast cancer. Samsung Bioepis reported that five year...

Pearce IP BioBlast®: w/e 10 September 2021

02 Sep 21 | US | Amgen and Hospira appear ready to settle the ongoing dispute relating to Neupogen® (filgrastim). The matter was due to go to a jury trial on 20 September 2021. 06 Sep 21 | IN | Hetero announced that it has received emergency use...

Pearce IP BioBlast®: w/e 03 September 2021

26 Aug 21 | US | Two former executives of JHL Biotech plead guilty to conspiracy to steal trade secrets and commit wire fraud exceeding $101 million in the US District Court for the Northern District of California. The written plea agreements...

Pearce IP BioBlast®: w/e 27 August 2021

24 Aug 21 | UCB announced that it has gained EU marketing approval for Bimzelx® (bimekizumab), an IL-17A and IL-17F inhibitor indicated for the treatment of adults with moderate to severe plaque psoriasis. 25 Aug 21 | Cipla and Kemwell Biopharma...

Pearce IP BioBlast®: w/e 20 August 2021

17 Aug 21 | US | The USPTO Patent Trial and Appeal Board (PTAB) will review Amgen’s US 8,273,707 Patent (related to NEULASTA® (pegfilgrastim) in an IPR challenge brought by Pfizer and Hospira.  The PTAB declined to deny institution in view of...

Share This